Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

A new pill could be the future of treatment late-stage pancreatic cancer in the U.S., nearly doubling the length patients ...

Elraglusib plus chemotherapy doubled one-year survival in metastatic pancreatic cancer, showing improved outcomes in a phase ...

Engaging in moderate to vigorous physical activity, even below recommended levels, can significantly improve cancer survival ...

For more than two decades, oncologists treating advanced pancreatic cancer have watched new drugs fail to move the survival ...

An investigational targeted therapy doubled survival compared with standard chemotherapy for pretreated individuals with ...

Daraxonrasib delivered a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy in previously ...

Revolution Medicines reported positive results from a Phase 3 trial of its experimental drug daraxonrasib in patients with ...

For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and ...

By Sriparna Roy April 13 (Reuters) - Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live ...

A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National ...

Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases.